Incyte Corporation's (NASDAQ: INCY) Jakafi is the only approved treatment for myelofibrosis, and that's turned Jakafi into a billion-dollar blockbuster drug. The company's enviable market position could be coming to an end, though, because two competing drugs are making their way toward the FDA.Can Incyte maintain its dominance in this indication or will new drugs from Celgene (NASDAQ: CELG) and Geron Corp (NASDAQ: GERN) carve away at Jakafi's sales.Image source: Getty Images.A big need for new treatmentMyelofibrosis is a tough-to-treat bone marrow disease with a poor prognosis and limited treatment options. It leads to an enlarged spleen, fatigue, and pain. Over time, it can turn into life-threatening leukemia.The disease is characterized by decreased production of red blood cells in the bone marrow caused by scarring resulting from the overproliferation of abnormal cells. The only curative treatment is a bone marrow transplant; however, high mortality rates and complications make … [Read more...] about Incyte Could Have a Problem (or 2!) on Its Hands
Even though Apple (NASDAQ: AAPL) recorded record revenue and earnings per share (EPS) in the first quarter of 2018, questions remain about the company's long-term prospects.That's at least in part because the company has struggled to create a hit product since it released iPhone in 2007. Of course, that's a very high standard as Apple Watch and Apple TV would be considered successful products at most companies.Apple has created a very high bar for itself. That at least raises the question as to whether investors should buy shares in the company or whether its best days are behind it.Apple generally releases a new iPhone or at least a refresh in the fall. Image source: Apple.The numbers look goodOn a purely numerical basis, Apple has been killing it. The company posted Q1 2018 revenue of $88.3 billion, a 13% increase over the same period a year ago. Earnings per share (EPS) were up over 2017 as well climbing 16% to $3.89."We're thrilled to report the biggest quarter in Apple's history, … [Read more...] about Is Apple Inc. a Buy?
NVIDIA's (NASDAQ: NVDA) stock surged nearly 140% over the past 12 months, and almost 1,000% over the past three years. Those massive gains were mostly fueled by the chipmaker's dominance of the gaming GPU market, its expansion into the data center GPU market, and the rising use of its Tegra CPUs in connected cars.However, NVIDIA isn't particularly cheap today at nearly 40 times forward earnings, and investors might be wondering if other catalysts could lift the stock to new highs. So today I'll take a closer look at NVIDIA's three next-gen GPUs, and discuss how they could widen its moat against the competition.NVIDIA's Tesla V100. Image source: NVIDIA.VoltaNVIDIA introduced the Volta architecture, which uses 12nm transistors, in two high-end cards (the Tesla V100 and Titan V) last year. At the time, most analysts believed that Volta would be the direct successor to Pascal, its current-gen architecture, which uses 14nm to 16nm transistors.The Tesla V100 was designed for data centers, … [Read more...] about NVIDIA’s Next-Gen GPUs: What Investors Should Know
It looked like NVIDIA (NASDAQ: NVDA) would run away with the GPU (graphics processing unit) market by steamrolling Advanced Micro Devices (NASDAQ: AMD) with a superior product line-up. But the latest market share numbers from Jon Peddie Research indicate that AMD can punch above its weight.The two graphics specialists have been engaged in a bitter war for GPU market share, and AMD had the upper hand toward the beginning of 2017. However, its Vega graphics cards turned out to be disappointing. They consumed more power, didn't deliver enough performance gains, and weren't priced competitively enough. Still, AMD managed to make gains against its larger rival during the holiday quarter. Let's see what happened and why.Image source: AMD.comWhat happened?AMD's discrete GPU market share expanded to 33.7% during the fourth quarter, up from 29.5% in the prior-year period, with NVIDIA commanding the rest.This growth in AMD's business, despite an unappealing product line-up, seems surprising at … [Read more...] about AMD Makes a Big Dent in NVIDIA’s Graphics Business
Recreational vehicle giant Winnebago (NYSE: WGO) has benefited from a mix of good luck and solid execution lately. Shares trounced the market in 2017 as the RV industry completed its eighth straight year of healthy expansion. Winnebago made the most of that positive momentum, too, as an acquisition of a competitor filled out its portfolio and delivered soaring sales gains last year.The company is aiming to extend its growth into 2018 with fiscal second-quarter earnings due out on Wednesday, March 21. Let's take a look at what investors can expect from that report.Image source: Getty Images.Dealership inventoryWall Street expects Winnebago to post sales of roughly $442 million, which would translate into a 19% gain over the prior-year period. The boost would mark a sharp deceleration from the prior quarter's 83% revenue spike, but only because a full year has now passed since the company added Grand Design and its portfolio of towable RV products to its sales base.Winnebago's last … [Read more...] about Winnebago Earnings: 3 Things to Watch